SEC Comment Letter 0000000000-24-009295 to EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102) (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102)
Date: Aug. 14, 2024 · CIK: 0001314102 · Accession: 0000000000-24-009295
AI Filing Summary & Sentiment
File numbers found in text: 333-281391
Letter
August 14, 2024 Jay S. Duker Chief Executive Officer EyePoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown, MA 02472 Re:EyePoint Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 8, 2024 File No. 333-281391 Dear Jay S. Duker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Stephen M. Nicolai
Show Raw Text
August 14, 2024
Jay S. Duker
Chief Executive Officer
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown, MA 02472
Re:EyePoint Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 8, 2024
File No. 333-281391
Dear Jay S. Duker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Stephen M. Nicolai